imipramine has been researched along with thyrotropin-releasing hormone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuchi, T; Kurahashi, N; Miwa, T; Nishi, T; Oshiro, Y; Sakurai, Y; Sato, S; Tanaka, T; Tottori, K; Uwahodo, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for imipramine and thyrotropin-releasing hormone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for imipramine and thyrotropin-releasing hormone
| Article | Year |
|---|---|
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
Topics: Animals; Antidepressive Agents; Brain Concussion; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred ICR; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, sigma; Structure-Activity Relationship | 2000 |